GAMMAGARD LIQUID: payments to doctors
Payments that named GAMMAGARD LIQUID as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $317K
- Providers
- 174
- Transactions
- 456
- Average per transaction
- $695
The per-transaction average — $695 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 174 providers the average total is $1,821, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $264,030 | 83.3% |
| Shire North American Group Inc | $52,908 | 16.7% |